Christopher Waddick
Director of Finance/CFO bei CARDIOL THERAPEUTICS INC.
Vermögen: 199 100 $ am 31.03.2024
Profil
Christopher J.
Waddick is currently the Chief Financial Officer, Secretary & Director at Cardiol Therapeutics, Inc. since 2022.
He is also the President & Chief Financial Officer at Active Energy, Inc. since 2013 and the President at Nrj Consulting, Inc. since 2009.
Previously, he served as the Chief Financial & Executive Officer at Vasogen, Inc. from 2007 to 2009.
Mr. Waddick holds an MBA from York University and an undergraduate degree from Wilfrid Laurier University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 29.02.2024 | 110 000 ( 0,17% ) | 199 100 $ | 31.03.2024 |
Aktive Positionen von Christopher Waddick
| Unternehmen | Position | Beginn |
|---|---|---|
| CARDIOL THERAPEUTICS INC. | Director of Finance/CFO | 16.08.2018 |
Active Energy, Inc.
 Active Energy, Inc. Electric UtilitiesUtilities Active Energy, Inc. operates as an energy management firm. It offers energy assessment, electricity products and services, natural gas products and services, and cap and trade. The company is headquartered in Burlington, Canada. | Director of Finance/CFO | 01.01.2013 |
| Nrj Consulting, Inc. | President | 01.11.2009 |
Ehemalige bekannte Positionen von Christopher Waddick
| Unternehmen | Position | Ende |
|---|---|---|
Vasogen, Inc.
 Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Chief Executive Officer | - |
Ausbildung von Christopher Waddick
| York University | Masters Business Admin |
| Wilfrid Laurier University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| CARDIOL THERAPEUTICS INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Health Technology |
Active Energy, Inc.
Active Energy, Inc. Electric UtilitiesUtilities Active Energy, Inc. operates as an energy management firm. It offers energy assessment, electricity products and services, natural gas products and services, and cap and trade. The company is headquartered in Burlington, Canada. | Utilities |
| Nrj Consulting, Inc. |
